drugset / Trial / NCT01089998
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-9596 in patients with cancer and inflammation
Timeline
- Start
- 2010-05
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY86-9596 | Diagnostic / imaging agent | 200 mbq | Intravenous |
| Subject | BAY86-9596 | Diagnostic / imaging agent | 300 mbq | Intravenous |
| Subject | Fludeoxyglucose (18F)-IBA | Unknown | — | — |
Indications
No indication recorded.